Imatinib-d_8

Cat. No.:	HY-15463S
CAS No.:	1092942-82-9
Molecular Formula:	$C_{29}H_{23}D_8N_7O$
Molecular Weight:	501.65
Target:	Bcr-Abl; PDGFR; c-Kit; Autophagy; SARS-CoV
Pathway:	Protein Tyrosine Kinase/RTK; Autophagy; Anti-infection



Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

BIOLOGICAL ACTIVITY

Description

Imatinib-d_8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

CUSTOMER VALIDATION

- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.

[2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

[3]. Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924-8933. Published 2016 Sep 12.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA